COAPT试验:残余二尖瓣反流与心衰临床及生活质量结局的关系
COAPT随机试验纳入614例心衰合并3+或4+继发性二尖瓣反流患者,比较经导管二尖瓣修复(TMVr)与单纯指南导向药物治疗(GDMT)。分析30天残余二尖瓣反流严重程度与30天至2年结局的关系,发现30天残余反流越轻,死亡或心衰住院复合终点发生率越低,生活质量改善得以维持,且TMVr与GDMT两臂一致。
要点
- 30天残余二尖瓣反流0/1+、2+、3+/4+患者30天至2年死亡或心衰住院率分别为37.7%、49.5%、72.2%(P<0.0001)。
- 30天残余反流≤2+者生活质量改善维持至2年,3+/4+者恶化(-0.3±1.7 vs -9.4±4.6,P=0.0008)。
- 残余反流与结局的关系在TMVr和GDMT两臂中一致(交互P=0.92和0.95)。
核心结论
- COAPT试验中,30天时二尖瓣反流减轻与更高的无死亡或心衰住院生存率及更好的生活质量相关,无论反流减轻是通过TMVr还是GDMT实现。
研究设计与样本
- 随机对照试验COAPT的事后分析,纳入614例心衰合并3+或4+继发性二尖瓣反流患者,比较TMVr与单纯GDMT。
- 依据30天残余二尖瓣反流严重程度,分析30天至2年的结局。
主要发现
- TMVr组30天残余反流0/1+、2+、3+/4+比例分别为72.9%、19.9%、7.2%,GDMT组分别为8.2%、26.1%、65.8%(P<0.0001)。
- 30天残余反流0/1+、2+、3+/4+患者30天至2年死亡或心衰住院复合终点发生率分别为37.7%、49.5%、72.2%(P<0.0001)。
- 该关系在TMVr和GDMT两臂中一致(交互P=0.92)。
- 30天残余反流≤2+者KCCQ评分从基线至30天的改善维持至2年,3+/4+者恶化(-0.3±1.7 vs -9.4±4.6,P=0.0008),两臂一致(交互P=0.95)。
临床怎么用
- TMVr或GDMT治疗后应评估30天残余二尖瓣反流程度,残余反流≤2+提示预后较好。
- 30天残余反流3+/4+与较高的死亡或心衰住院风险及生活质量恶化相关,需加强关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation), among 614 patients with heart failure with 3+ or 4+ secondary mitral regurgitation (MR), transcatheter mitral valve repair (TMVr) with the MitraClip reduced MR, heart failure hospitalizations, and mortality and improved quality of life compared with guideline-directed medical therapy (GDMT) alone. We aimed to examine the prognostic relationship between MR reduction and outcomes after TMVr and GDMT alone. METHODS: Outcomes in COAPT between 30 days and 2 years were examined on the basis of the severity of residual MR at 30 days. RESULTS: TMVr-treated patients had less severe residual MR at 30 days than GDMT-treated patients (0/1+, 2+, and 3+/4+: 72.9%, 19.9%, and 7.2% versus 8.2%, 26.1%, and 65.8%, respectively [P<0.0001]). The rate of composite death or heart failure hospitalizations between 30 days and 2 years was lower in patients with 30-day residual MR of 0/1+ and 2+ compared with patients with 30-day residual MR of 3+/4+ (37.7% versus 49.5% versus 72.2%, respectively [P<0.0001]). This relationship was consistent in the TMVr and GDMT arms (Pinteraction=0.92). The improvement in Kansas City Cardiomyopathy Questionnaire score from baseline to 30 days was maintained between 30 days and 2 years in patients with 30-day MR ≤2+ but deteriorated in those with 30-day MR 3+/4+ (-0.3±1.7 versus -9.4±4.6 [P=0.0008]) consistently in both groups (Pinteraction=0.95). CONCLUSIONS: In the COAPT trial, reduced MR at 30 days was associated with greater freedom from death or heart failure hospitalizations and improved quality of life through 2-year follow-up whether the MR reduction was achieved by TMVr or GDMT. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01626079.
引用
- Kar S, Mack MJ, Lindenfeld J, et al. Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure: COAPT Trial. Circulation. 2021. PMID: 34039025. doi:10.1161/CIRCULATIONAHA.120.053061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。